Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. It has a collaboration agreement with Rentschler Fill Solutions GmbH. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio10.10
Quick Ratio10.06
Price-To-Earnings
Trailing P/E Ratio-11.19
Forward P/E Ratio-16.03
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.61 million
Price / Sales1,620.10
Cash FlowN/A
Price / CashN/A
Book Value$8.68 per share
Price / Book9.79
Profitability
EPS (Most Recent Fiscal Year)($7.50)
Net Income$-302,130,000.00
Net MarginsN/A
Return on Equity-46.22%
Return on Assets-39.24%
Miscellaneous
Employees520
Outstanding Shares49,770,000
Market Cap$4,214.72
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its earnings results on Monday, May, 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.81. The biopharmaceutical company earned $10.68 million during the quarter, compared to analyst estimates of $56.58 million. During the same quarter in the previous year, the firm posted ($1.63) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
21 Wall Street analysts have issued 1-year target prices for Ultragenyx Pharmaceutical's shares. Their predictions range from $55.00 to $95.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $71.8947 in the next twelve months. This suggests that the stock has a possible downside of 15.8%. View Analyst Ratings for Ultragenyx Pharmaceutical.
What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/30/2018)
- 2. JPMorgan Chase & Co. analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Genmab A/S (GNMSF), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Catalent (CTLT).
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Dr. Emil D. Kakkis, Pres, CEO & Director (Age 58)
- Ms. Shalini Sharp, CFO & Exec. VP (Age 43)
- Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 58)
- Mr. John Richard Pinion II, Chief Quality Officer & Exec. VP of Translational Sciences (Age 52)
- Mr. Theodore A. Huizenga, VP, Corp. Controller & Principal Accounting Officer (Age 47)
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
Media headlines about RARE stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 0.05 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 43.41 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Ultragenyx Pharmaceutical's major shareholders?
Ultragenyx Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include Fred Alger Management Inc. (0.47%), Xact Kapitalforvaltning AB (0.01%) and Amalgamated Bank (0.01%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.
Which institutional investors are selling Ultragenyx Pharmaceutical stock?
RARE stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
Which institutional investors are buying Ultragenyx Pharmaceutical stock?
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $85.38.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $4.21 billion and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.50) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
